Alimera Sciences announced a change to the Summary of Product Characteristics (SmPC) for its intravitreal implant, Iluvien (190 micrograms of fluocinolone acetonide), a treatment for vision impairment associated with chronic diabetic macular oedema (DMO).
The new update extended the authority to administer this treatment to all qualified ophthalmic healthcare professionals in the UK experienced in intravitreal injections - where previously only ophthalmologists were authorised.
Peter Addison, consultant ophthalmic surgeon and deputy director Uveitis and Scleritis at Moorfields Eye Hospital Foundation Trust, noted: ‘Expanding the skill set of the nurse injectors in my clinic to include Iluvien has streamlined our workflow and allowed us to better manage patient care.’
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here
